Humana (NYSE:HUM) Issues FY24 Earnings Guidance

Humana (NYSE:HUM) updated its FY24 earnings guidance on Wednesday. The company provided EPS guidance of approx. $16.00 for the period, compared to the consensus EPS estimate of $16.35.

Wall Street Analyst Weigh In

Several research firms recently commented on HUM. Stephens cut their target price on shares of Humana from $550.00 to $430.00 and set an overweight rating for the company in a research note on Friday, January 26th. Wells Fargo & Company cut their target price on shares of Humana from $413.00 to $350.00 and set an overweight rating for the company in a research note on Monday, April 8th. Deutsche Bank Aktiengesellschaft cut shares of Humana from a buy rating to a hold rating and cut their target price for the company from $595.00 to $360.00 in a research note on Thursday, January 25th. TheStreet cut shares of Humana from a b rating to a c+ rating in a research note on Monday, January 8th. Finally, Cantor Fitzgerald reiterated a neutral rating and set a $391.00 target price on shares of Humana in a research note on Wednesday, April 10th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Humana presently has an average rating of Hold and a consensus price target of $454.63.

Humana Price Performance

Shares of HUM traded down $11.94 during trading hours on Wednesday, hitting $316.04. The stock had a trading volume of 3,488,066 shares, compared to its average volume of 2,006,808. The company’s fifty day moving average is $329.86 and its two-hundred day moving average is $398.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59. Humana has a 52 week low of $299.23 and a 52 week high of $541.21. The stock has a market capitalization of $38.13 billion, a price-to-earnings ratio of 15.95, a P/E/G ratio of 1.91 and a beta of 0.45.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a net margin of 2.34% and a return on equity of 19.44%. The business had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the prior year, the firm earned $9.38 EPS. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, analysts anticipate that Humana will post 16.06 EPS for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.12%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio is currently 17.86%.

Insiders Place Their Bets

In related news, Director Jorge S. Mesquita acquired 545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, with a total value of $200,064.05. Following the acquisition, the director now directly owns 2,578 shares in the company, valued at $946,358.02. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.29% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.